Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RUBY-J: dostarlimab plus carboplatin-paclitaxel in Japanese patients with advanced or recurrent endometrial cancer
jRCT2061230114Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- May 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dostarlimab, carboplatin and paclitaxel in endometrial cancer (EC), sponsored by GSK. Primary endpoint: Durable response rate for 12 months. Started May 2024; status: active, not recruiting.
02
Drugs
dostarlimabcarboplatinpaclitaxel
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on jRCT2061230114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061230114.